AllerT: Additional Phase I/IIa data

Additional data from the double-blind, placebo-controlled, Swiss Phase I/IIa AN003 trial in 18 evaluable patients showed that AllerT significantly increased mean allergen-specific IgG4 levels from baseline to 16-18 months after the last injection (2 months after the 2010 birch pollen season; p=0.0001). Patients receiving placebo showed no change in IgG4 levels at any time. Patients received 5 subcutaneous injections of AllerT or placebo over 2 months prior to the 2009 birch pollen season. ...